Axonics Modulation Technologies Inc (NASDAQ:AXNX) COO Rinda Sama sold 13,345 shares of the company’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $28.03, for a total value of $374,060.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
AXNX opened at $31.44 on Wednesday. Axonics Modulation Technologies Inc has a 12-month low of $11.95 and a 12-month high of $32.90. The company has a debt-to-equity ratio of 0.16, a quick ratio of 27.46 and a current ratio of 22.83. The firm has a market cap of $817.67 million and a PE ratio of -6.78.
Axonics Modulation Technologies (NASDAQ:AXNX) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.18). The firm had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.24 million. On average, equities analysts expect that Axonics Modulation Technologies Inc will post -1.66 EPS for the current year.
Several equities analysts have commented on AXNX shares. SunTrust Banks upped their price objective on Axonics Modulation Technologies to $26.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. Zacks Investment Research raised Axonics Modulation Technologies from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research report on Thursday, February 21st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $23.38.
Axonics Modulation Technologies Company Profile
Axonics Modulation Technologies, Inc, a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention.
Further Reading: Technical Analysis
Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.